PLRX Projected Dividend Yield
Pliant Therapeutics Inc ( NASDAQ : PLRX )Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. Co. is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of ?vß6 and ?vß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Co. has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of ?vß1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. 21 YEAR PERFORMANCE RESULTS |
PLRX Dividend History Detail PLRX Dividend News PLRX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |